EMJ GOLD - European Medical Journal

This site is intended for healthcare professionals

Continue

Pharma News, Views & Analysis

Filter Advertise With Us
Dollar bill on blue background

US government negotiates Medicare part B drugs

The CMS has unveiled the 15 high-cost medications selected for the next phase of the Medicare Drug Price Negotiation Program.
Scientist performing-experiment

When ELNs fall short: why R&D is turning to AI

A new study shows how limitations in electronic lab notebooks (ELNs) are driving pharma R&D teams to use AI tools, raising privacy concerns.
Person taking a survey on a tablet

Gen Z increasingly turning to AI for STI advice

A growing number of Gen Z are turning to AI chatbots for sexual health advice, including the diagnosis of sexually transmitted infections.
The world

Major philanthropies launch $60m AMR consortium

This first-of-its-kind global consortium aims to accelerate the discovery of treatments for the world’s most resistant pathogens.
Cartoon brain on green background

New drug could offer another way to treat stroke

Currently in phase 2 trials, BB-031 is the first new mechanistic approach to ischemic stroke treatment in nearly 30 years.
Pill on purple background

Paracetamol safety: New study finds no autism link

A review has provided evidence debunking claims that acetaminophen (paracetamol) use during pregnancy increases the risk of ASDand ADHD.
vaccine

FDA orders seizure warnings for major flu vaccines

The FDA has directed pharma companies of influenza vaccines to update their product labelling to include the risk of fever-induced seizures.
Person looking into distance with telescope at arrow pointing upwards

UK clinical trial applications on the rise, finds MHRA

The 9% growth in 2025 could signal that the country is on track to become a more attractive destination for pharamceutical R&D.
Month in pharma news, explained

Month in pharma news, explained - December 2025

In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on December 2025.
Handshake

Lilly and NVIDIA: a $1bn leap for drug discovery

Eli Lilly and NVIDIA have unveiled a first-of-its-kind AI co-innovation lab, aiming to solving the most complex bottlenecks in pharma.
desktop showing data

Pharma to FDA: upgrade cell and gene data sharing

The pharmaceutical industry is calling on the FDA to modernise how it tracks the long-term safety and efficacy of cell and gene therapies.
Two people making a handshake

J&J acquires Halda to take on cancer cell resistance

J&J successfully acquired Halda Therapeutics for $3.05bn integrating Halda’s RIPTAC platform into J&J’s oncology portfolio.
Pharma R&D cycle

End of lifelong pills? GSK’s phase 3 success in hepatitis B

GSK announced in January that its novel chronic hepatitis B successfully met primary goals in two pivotal phase 3 trials.
Vaccine administration

US slashes vaccine schedule: a major shift for paediatrics

CDC has formally reduced its routine childhood vaccine recommendations from 17 to 11, marking a major shift in US healthcare, read more.
Two US flags on beige background

Nine pharma giants sign on to Trump pricing deal

President Donald Trump has unveiled a new set of sweeping pricing deals with nine large drugmakers, according to a White House press release.
Handshake on blue background

GSK signs $17.5m RNA therapeutics pact with CAMP4

GSK has struck the collaboration to accelerate development of RNA-based therapies for neurodegenerative and renal disorders.
Door with light pouring out of it

NICE appoints Prof Jonathan Benger as new CEO

His appointment comes at a pivotal moment for the organisation, as NICE prepares to help deliver the 10 Year Health Plan for the NHS.
Gold coins on blue background

VPAG 2026 rate set at 14.5%, post US tariff deal

Industry leaders cautiously welcome the step but warn that more reform is needed if the UK is to regain its competitive edge.
Handshake on globe backdrop

US tariff deal: what it means for UK pharma

Last week, the UK and US signed a zero tariff pharmaceuticals deal, but what will the deal deliver in the long term, and is all as it seems?
Month in pharma news, explained

Month in pharma news, explained – November 2025

In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on November 2025.
Clinical trial participant

ABPI: UK falling behind on clinical trial recruitment

According to the body, patient participation in industry-sponsored trials has fallen by 25% between 2022/23 and 2024/25.
Vaccine

Europe’s vaccine pipeline has 91 candidates in R&D

Crucially, 41% of these candidates target pathogens for which no vaccines or prophylactic monoclonal antibodies are currently registered.
Cartoon brain on green background

Epileptic seizure detection device to launch in Europe

A wearable device that can alert patients and caregivers minutes before a seizure occurs is set to launch across Europe.
Doctor and patient discussing depression

AbbVie and BioMed X to study science of lost joy

The two companies have launched a collaborative research initiative to investigate anhedonia in depression, hoping to solve huge unmet needs.
We’ve noticed you’re accessing
from North/South America.